Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

NCT07396480 is registered in ClinicalTrials.gov with First Affiliated Hospital of Zhejiang University as lead sponsor.

NCT NCT07396480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07396480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
Lead sponsor
First Affiliated Hospital of Zhejiang University
Phase
Phase 3
Overall status
Recruiting
Start date
March 1, 2026
Completion date
June 30, 2030
Enrollment
186 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leucemia, allogeneic hematopoietic stem cell transplantation, conditioning, myeldysplastic syndrome (mds), myeloid malignancies, venentoclax